Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
about
Beta-thalassemiaOral deferiprone for iron chelation in people with thalassaemiaEfficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromesImpact of cardiac magnetic resonance imaging in non-ischemic cardiomyopathiesReview of Journal of Cardiovascular Magnetic Resonance 2011.Review of Journal of Cardiovascular Magnetic Resonance 2009International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers.Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overloadLow prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonanceTransition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases.Iron overload in polytransfused patients without heart failure is associated with subclinical alterations of systolic left ventricular function using cardiovascular magnetic resonance taggingOn improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure.Magnetic resonance comparison of left-right heart volumetric and functional parameters in thalassemia major and thalassemia intermedia patients.Heart Rate Variability as an Alternative Indicator for Identifying Cardiac Iron Status in Non-Transfusion Dependent Thalassemia PatientsManagement of transfusional iron overload - differential properties and efficacy of iron chelating agents.Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major.Estimating tissue iron burden: current status and future prospects.Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overloadTreating thalassemia major-related iron overload: the role of deferiprone.An update on iron chelation therapyFree-breathing myocardial T2* mapping using GRE-EPI and automatic non-rigid motion correction.Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamineCardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapyNew developments and controversies in iron metabolism and iron chelation therapy.On myocardial siderosis and left ventricular dysfunction in hemochromatosis.The Association between Serum Ferritin Level, Tissue Doppler Echocardiography, Cardiac T2* MRI, and Heart Rate Recovery in Patients with Beta Thalassemia Major.Management of the thalassemiasTreatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone.Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonanceInternational survey of T2* cardiovascular magnetic resonance in β-thalassemia majorThe efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study.Acute cardiac decompensation in a patient with beta-thalassemia and diabetes mellitus following cessation of chelation therapyCardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major.How early can myocardial iron overload occur in beta thalassemia major?Evaluation of myocardial iron overload using magnetic resonance imaging.A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).Assessment and treatment of cardiac iron overload in thalassemia.Beta-thalassemia.Post-mortem study of the association between cardiac iron and fibrosis in transfusion dependent anaemia.
P2860
Q21202886-590E020B-8791-47A5-BA29-50F2DE682511Q24200309-0C0BC4A5-A025-44CA-8E38-EC2A1CE0DDC8Q26764818-E6C4342C-80A9-4E97-B1CB-2BDD1996ABE3Q26765173-2637A9CD-2C94-4E41-9B09-87AD13A70819Q30459937-0EBD3FCC-59CA-4BE3-94CF-9CE726CA0B29Q30484444-9BF61F0D-2D84-4367-99F2-16045A4FA499Q34158260-FF34B799-F0F9-4312-80F5-5CDE0A748659Q34269245-16566B41-FD04-4399-8847-574A20B3FC4AQ34451527-452A7568-76F9-4AD7-ACF6-7030B2218333Q34515540-EDA1D8F0-A1F6-45F0-9880-A270A267B8BDQ34761250-69B23AC6-F1E0-4F04-8DB8-5E96A0B5AC05Q35027190-4C06AB10-E3AE-451D-AF84-12542573F495Q35232747-2E88FD5B-A46D-40D0-B897-2D075D3902ADQ35438051-41F52E29-F4FA-4B85-AF56-F185BBFF4D4BQ35665822-5FCF1EAE-7AC9-4E1A-A070-5A16E47D9590Q35683841-59D20C40-54C5-42E7-A9BB-F86DE45A86BFQ35753526-CC265D52-2527-4570-9399-C526CAB8706EQ35793545-59A7061F-9D03-4550-AB9D-249545E4FB74Q35813192-00E7B870-AF8E-4C7F-A073-BF1489C6F48BQ36344669-49248510-0442-49AD-A509-DAA29E583F25Q36393446-F1B89849-270F-4D9A-B45F-C1CD5692E93DQ36402144-8A152D3F-D156-42C5-BADE-6E0D1F93DBCDQ36498403-57DC3663-3A12-4DCE-AE2E-C5490A5E51CEQ36690349-72996643-4A15-4CD4-931C-5D62F923EBDCQ36719376-C3A97CCF-7C57-4FEF-B6E1-E49FE677DC71Q36752732-E1B77256-623D-4221-82A1-3E2F75EFBBDAQ36754372-E00F9F1D-80A3-438A-8AD5-B4181F6A6641Q36870253-2C04474C-6F25-487B-8C76-E19654D3F2F6Q36891845-47678F25-5389-4007-A068-F336653DC1D8Q36926651-32C3FFB7-D6E8-43E2-804B-E544AF7BEA48Q37144860-0D77D129-40ED-4703-A9D4-664F21BE6E5EQ37268421-BE7B59BF-6CB3-4007-8B75-9C1FAD90FA12Q37319367-B715A372-9207-4BEC-9A56-D610609322B4Q37442375-89A35E02-2665-4A98-B81D-1083E81A4E5BQ37504957-F95CCCD5-3274-48AA-9AB1-4E17BF9FD766Q37573422-FFA417F1-065F-4E9D-8402-B161E461C9D6Q37623523-BD676225-7AF7-40EB-BC6B-AC7A6BF9B705Q37650479-F9552AF4-DAE0-426F-A51E-F879EF7A0E3EQ37680651-69B10F93-8AC5-4305-ADC0-7310656B8CA0Q37721775-8BBEB1E6-9C0F-4E00-876C-13D0669B1266
P2860
Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Combined chelation therapy in ...... left ventricular dysfunction.
@ast
Combined chelation therapy in ...... left ventricular dysfunction.
@en
type
label
Combined chelation therapy in ...... left ventricular dysfunction.
@ast
Combined chelation therapy in ...... left ventricular dysfunction.
@en
prefLabel
Combined chelation therapy in ...... left ventricular dysfunction.
@ast
Combined chelation therapy in ...... left ventricular dysfunction.
@en
P2093
P2860
P356
P1476
Combined chelation therapy in ...... h left ventricular dysfunction
@en
P2093
Annalisa Agus
Carlo Dessi
Gillian C Smith
Mark A Tanner
Mark A Westwood
Martina Pibiri
Renzo Galanello
Sunil V Nair
P2860
P2888
P356
10.1186/1532-429X-10-12
P577
2008-02-25T00:00:00Z
P6179
1041787063